GIOTRIF® :
The 1^st choice in 1^st-line

Superior efficacy vs gefitinib and vs chemotherapy
demonstrated in 3 large trials in 1^st-line EGFR M+ NSCLC^1-4*

GIOTRIF® significantly reduces the relative risk in disease progression or death vs gefitinib in NSCLC

Document ID: PC-MY-102821

03/02/2023

Author: Boehringer Ingelheim

123,000
Views

100k 340